Primary Retroperitoneal Mucinous Cystadenocarcinoma: A Case Report and Literature Summary

Jianhuang Li,Jian Li,Zhongliang Hu,Xiong Guo,Zeming Jia,Ling Lin,Lin Zhou,Yaping Tang,Yuxiang Chen
DOI: https://doi.org/10.1166/jnn.2016.12976
2016-01-01
Journal of Nanoscience and Nanotechnology
Abstract:To discuss the pathology and clinic of primary retroperitoneal mucinous cystadenocarcinoma (PRMA), we report a case of primary retroperitoneal mucinous cystadenocarcinoma with retrospective analysis, and search the database of PubMed and Embase to summarize the related literatures. After systematic analysis, the final result is proved to be primary retroperitoneal mucinous cystadenocarcinoma by postoperative pathological examination. It is also found that the patient received 4 treatment cycles of chemotherapy regimens (paclitaxel 270 mg, carboplatin 0.5 g) after surgery. There is no recurrence in the follow-up after 16 months of operation. It is concluded that primary retroperitoneal mucinous cystadenocarcinoma is an uncommon neoplasma, its original tissue is still obscure and it can be diagnosed only by pathological examination. The basic and essential method of therapy is to remove the lesion by surgical or trans-laparoscope. Total hysterectomy with bilateral salpingo-oophorectomy is recommended for childbearing female patients. Adjuvant chemotherapy may improve the prognosis, but there is no an overall review of it up to date.
What problem does this paper attempt to address?